All In Biotech

Drug Trial Radar · NCT06742190

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

154

Actual

Start

Dec 18, 2024

Primary completion

Sep 2026

Study completion Dec 2029

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion

Conditions

  • Multifocal Motor Neuropathy (MMN)
  • MMN

Interventions

  • EmpasiprubartBiological

    Intravenous infusion of empasiprubart

  • IVIG (Intravenous Immunoglobulin)Biological

    Intravenous infusion of IVIg

  • Empasiprubart-placeboOther

    A placebo resembling the empasiprubart treatment

  • IVIg-placeboOther

    A placebo resembling the IVIg treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in grip strength (4-week average) in the most affected hand at week 24Time frame: Up to 24 weeks

Locations

109 sites in 26 countries. Site status is shown where the registry gives one.

  • HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology

    Scottsdale, Arizona

  • The Neurology Group

    Pomona, California

  • Samir Macwan, M.D., Inc.

    Rancho Mirage, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic)

    Aurora, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Medstar Health Research Institute

    Washington D.C., District of Columbia

  • EZR Research LLC

    Boca Raton, Florida

  • Healthcare Innovations Institute, LLC

    Coral Springs, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Fairway, Kansas

  • Perelman Center for Advanced Medicine

    Columbia, Maryland

  • UC Irvine - MDA ALS and Neuromuscular Center

    Columbia, Maryland

  • University of Minnesota

    Minneapolis, Minnesota

  • Dent Neurologic Institute Amherst

    Amherst, New York

  • Columbia University Medical Center

    New York, New York

  • University of North Carolina at Chapel Hill

    Morrisville, North Carolina

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • National Neuromuscular Research Institute

    Austin, Texas

  • NeuroCarePlus

    Houston, Texas

  • Royal Melbourne Hospital

    Parkville, Australia

  • Gold Coast University Hospital

    Southport, Australia

  • Brain and Mind Center

    Sydney, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Universitätsklinikum AKH Wien

    Vienna, Austria

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Hôpital de la Citadelle

    Liège, Belgium

  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto

    Ribeirão Preto, Brazil

  • Sociedade de Ensino Superior Estacio de Sa Ltda

    Rio de Janeiro, Brazil

  • Escola Bahiana de Medicina e Saude Publica

    Salvador, Brazil

  • PSEG Centro de Pesquisa Clínica

    São Paulo, Brazil

  • Neuro-Outaouais Clinic

    Gatineau, Canada

  • London Health Sciences Centre

    London, Canada

  • St. Paul's Neurology Associates

    Vancouver, Canada

  • Huashan Hospital Fudan University

    Shanghai, China

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.